- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02702999
Determination of Abnormal Fetal Growth or Amniotic Fluid With Third Trimester Ultrasounds in Uncomplicated Pregnancies: A Randomized Trial (UP)
Determination of Abnormal Fetal Growth or Amniotic Fluid With Third Trimester Ultrasounds in Uncomplicated Pregnancies: A Randomized Trial (UP Trial)
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Texas
-
Bellaire, Texas, Estados Unidos, 77401
- UT Physicians
-
Houston, Texas, Estados Unidos, 77030
- University of Texas at Houston Health Science Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Maternal age of 18 at the time of consent
- Singleton gestation
Exclusion Criteria:
- First sonographic examination after 20 weeks
- Women with any of the following co-morbidities: Autoimmune disorders (antiphospholipid antibody, lupus, rheumatoid arthritis, scleroderma), Cerclage in the index pregnancy, Diabetes mellitus-gestational or pre-gestational, Hematologic disorders (coagulation defects, sickle cell disease, thrombocytopenia, thrombophilia), Hypertension (chronic or pregnancy induced) before enrollment, HIV (human immunodeficiency virus), Institutionalized individuals (prisoners), Prior obstetric history of: [1) intrauterine growth restriction, 2) preterm birth before 34 weeks, 3) severe preeclampsia], eclampsia, HELLP syndrome, and 4) stillbirth after 24 weeks or neonatal death, Preterm labor or ruptured membranes before enrollment, Psychiatric disorder (bipolar, depression) on medication, Placenta previa / 3rd trimester bleeding, Renal insufficiency (serum creatinine > 1.5 mg/dL), Restrictive lung disease, Fetal red blood cell isoimmunization, Seizure disorder on medication, Thyroid disease on medication, Body Mass Index (BMI) above 40 kg/m2
- Major fetal Anomaly including: anencephaly, spina bifida, bilateral renal agenesis, cystic hygroma with hydrops, diaphragmatic hernia, or congenital heart defects
- Unable to understand consent in English or Spanish
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Routine third trimester care
Routine third trimester care with clinically-indicated ultrasound (control)
|
Routine third trimester care with clinically-indicated ultrasound (control)
|
Experimental: Serial third trimester ultrasound
Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group).
Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
|
Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group).
Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Participants With Fetal Growth Restriction
Periodo de tiempo: 30 to 38 weeks gestational age
|
30 to 38 weeks gestational age
|
|
Number of Participants With Large for Gestational Age Fetuses
Periodo de tiempo: 30 to 38 weeks gestational age
|
30 to 38 weeks gestational age
|
|
Number of Participates With Oligohydraminos
Periodo de tiempo: 30 to 38 weeks gestational age
|
Oligohydramnios is a condition in pregnancy characterized by a deficiency of amniotic fluid. Amniotic fluid was assessed using the amniotic fluid index (AFI) or maximum vertical pocket (MVP). Oligohydramnios was defined as AFI less than or equal to 5.0 cm or MVP less than or equal to 2.0 cm. AFI is the sum of the vertical length of the deepest, unobstructed pocket of amniotic fluid in each of the 4 quadrants of the pregnant uterus. An AFI of less than or equal to 5cm is considered low amniotic fluid, and an AFI greater than or equal to 24cm is considered high amniotic fluid. MVP is the vertical length of the single deepest pocket of amniotic fluid. An MVP less than or equal to 2cm is considered to be low amniotic fluid and an MVP of 8cm or greater is considered to be high amniotic fluid. Both low and high amniotic fluid levels are worse outcomes than having normal amniotic fluid levels. |
30 to 38 weeks gestational age
|
Number of Participates With Polyhydraminos
Periodo de tiempo: 30 to 38 weeks gestational age
|
Polyhydraminos is a condition in pregnancy characterized by an excess of amniotic fluid. Amniotic fluid was assessed using either the amniotic fluid index (AFI) or maximum vertical pocket (MVP). Polyhydramnios was defined as AFI greater than or equal to 24.0 cm or MVP greater than or equal to 8.0 cm. AFI is the sum of the vertical length of the deepest, unobstructed pocket of amniotic fluid in each of the 4 quadrants of the pregnant uterus. An AFI of less than or equal to 5cm is considered low amniotic fluid, and an AFI greater than or equal to 24cm is considered high amniotic fluid. MVP is the vertical length of the single deepest pocket of amniotic fluid. An MVP less than or equal to 2cm is considered to be low amniotic fluid and an MVP of 8cm or greater is considered to be high amniotic fluid. Both low and high amniotic fluid levels are worse outcomes than having normal amniotic fluid levels. |
30 to 38 weeks gestational age
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Participants With Composite Neonatal Morbidity
Periodo de tiempo: From time of delivery to 28 days after delivery
|
Composite Neonatal Morbidity is defined as the presence of one or more of the following: 1) Apgar score < 5 at 5 min; 2) umbilical arterial pH < 7.00; 3) intraventricular hemorrhage grade III or IV; 4) periventricular leukomalacia; 5) intubation for over 24 hrs; 6) necrotizing enterocolitis grade 2 or 3; 7) stillbirth; or 8) death within 28 days of birth.
|
From time of delivery to 28 days after delivery
|
Number of Participants With Composite Maternal Morbidity
Periodo de tiempo: From time of delivery to discharge (average time of discharge is 4 days after delivery)
|
Composite Maternal Morbidity is defined as the presence of one of more of the following: 1) chorioamnionitis; 2) cesarean delivery in labor; 3) wound infection; 4) transfusion; 5) deep venous thrombus or pulmonary embolism; 6) admission to intensive care unit; 7) postpartum hemorrhage; or 8) death.
|
From time of delivery to discharge (average time of discharge is 4 days after delivery)
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Olaide A Ashimi Balogun, MD, The University of Texas Health Science Center, Houston
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- HSC-MS-16-0084
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Clinically-indicated ultrasound
-
ReCor Medical, Inc.ReclutamientoHipertensiónAlemania, Países Bajos, Bélgica, Francia, Mónaco, Suiza, Reino Unido
-
Medical Corps, Israel Defense ForceReclutamientoLesiones Traumáticas | Herida de hemorragiaIsrael
-
Academisch Medisch Centrum - Universiteit van Amsterdam...TerminadoMedición Doppler de la arteria uterinaPaíses Bajos
-
Riverside University Health System Medical CenterDesconocidoPacientes en estado de shock e intubados en Trauma Bay (TB)Estados Unidos
-
Helse Nord-Trøndelag HFNorwegian University of Science and Technology; St. Olavs HospitalTerminadoCarrera | Ataque isquémico transitorio | Ataque Isquémico, Transitorio | Accidente cerebrovascular | Apoplejía cerebrovascularNoruega
-
Ajou University School of MedicineTerminadoEstenosis de la arteria coronariaCorea, república de